Search clinical trials for: Dopamine D2 Receptor

Total 21794 results

Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia (PERTAIN)

Schizophrenia

Poland, Israel, Romania, Germany, Lithuania, Croatia, France
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.

Schizoaffective Disorder | Psychotic Disorder
Janssen-Cilag, S.A.

Completed

Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia (PERFLEX)

Schizophrenia

Colombia, Argentina
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder

Mood Disorders | Bipolar Disorder
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Bioequivalence Study of 15 mg ER OROS Paliperidone

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate

Schizophrenia
Peking University

Recruiting

Treatment Strategy for Stage IV Gastric Cancer With Positive Peritoneal Cytology as the Only Non-curable Factor (Cy-plus)

Stomach Neoplasm

China
Duke University

Completed

Metoclopramide Versus Placebo for GJ Placement

Enteral Nutrition | Radiation Exposure

United States
Pharmathen S.A.

Completed

A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment

Schizophrenia

Jordan
University of Alabama at Birmingham
Ortho-McNeil Janssen Scientific Affairs, LLC; American Foundation for Suicide...

Completed

Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation (AFSP)

Suicidal Ideation | Major Depressive Disorder

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients

Schizophrenia

United States, India, Romania, Russian Federation, Ukraine
Janssen-Cilag S.p.A.

Completed

Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years

Schizophrenia
Janssen Pharmaceutica

Completed

A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia

Schizophrenia
Massachusetts General Hospital

Terminated

Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder

Pediatric Bipolar Disorder

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function

Schizophrenia | Renal Impairment
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Dose-proportionality Study of Five Tablet Strengths of ER OROS Paliperidone

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder

Bipolar Disorder | Mania | Affective Psychosis, Bipolar
Mahidol University
Siriraj Hospital

Completed

Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis After Receiving Cisplatin

Cancer

Thailand
University of Alberta
Natural Sciences and Engineering Research Council, Canada

Active, not recruiting

The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise

Health

Canada
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)

Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis

United States
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS Paliperidone

Schizophrenia
Xijing Hospital
Xi'an Central Hospital; First Affiliated Hospital Xi'an Jiaotong University; Tang-Du... and other collaborators

Terminated

Optimizing Early Enteral Nutrition in Severe Stroke (OPENS)

Dysphagia | Acute Stroke | Severe Stroke

China
Janssen Korea, Ltd., Korea

Completed

A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate

Schizophrenia

Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder

Mood Disorders | Bipolar Disorder

United States, Taiwan, Russian Federation, Turkey, Ukraine, Greece, Korea, Republic of, Lithuania
Janssen-Cilag Ltd.

Completed

A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation

Schizophrenia

France, Germany, Spain, Israel, Malaysia, Turkey, Taiwan, Greece, Korea, Republic of, Russian Federation, Netherlands, United Kingdom, Croatia, Denmark, Saudi Arabia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

Schizophrenia

United States, Ukraine, Germany, Spain, India, Russian Federation, Czech Republic, Austria, Hungary, Lithuania, Bulgaria, Estonia, Poland, France
Xian-Janssen Pharmaceutical Ltd.

Completed

A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia

Schizophrenia

China
Janssen-Cilag Ltd.,Thailand

Completed

Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants (PRESENT)

Schizophrenia

Thailand
Janssen Pharmaceutical K.K.

Completed

A Long-Term Study of JNS007ER in Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function

Schizophrenia | Hepatic Impairment
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorders
Ain Shams University
Future University in Egypt

Completed

The Effect of Prucalopride on Gastric Emptying in Intensive Care Unit Patients

Enteral Feeding Intolerance

Egypt
University of Malaya

Completed

Role of Prophylactic Metoclopramide With Tramadol in Trauma Patients

Trauma | Opioid Analgesic Adverse Reaction

Malaysia
Indiana University School of Medicine
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Study of Paliperidone ER in Adolescents and Young Adults With Autism

Autism

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of QT and QTc Intervals in Patients Administered Immediate Release Paliperidone

Schizophrenia | Schizoaffective Disorder
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia

Schizophrenia

Poland, United States, Belgium, Taiwan, Spain, Malaysia, Korea, Republic of, Thailand, Slovakia, Croatia
Taipei City Hospital
Johnson & Johnson Taiwan Ltd; Taipei Institute of Pathology

Completed

Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER

Schizophrenia | Schizoaffective Disorder

Taiwan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia

Schizophrenia
Janssen-Cilag Farmaceutica Ltda.

Completed

A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone

Schizophrenia

Brazil

3

Subscribe